US20060246045A1 - Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concertration - Google Patents

Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concertration Download PDF

Info

Publication number
US20060246045A1
US20060246045A1 US10/514,188 US51418805A US2006246045A1 US 20060246045 A1 US20060246045 A1 US 20060246045A1 US 51418805 A US51418805 A US 51418805A US 2006246045 A1 US2006246045 A1 US 2006246045A1
Authority
US
United States
Prior art keywords
methane
subjects
ibs
diarrhea
constipation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/514,188
Other languages
English (en)
Inventor
Mark Pimentel
Henry Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Priority to US10/514,188 priority Critical patent/US20060246045A1/en
Assigned to CEDARS-SINAI MEDICAL CENTER reassignment CEDARS-SINAI MEDICAL CENTER ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LIN, HENRY C., PIMENTEL, MARK
Publication of US20060246045A1 publication Critical patent/US20060246045A1/en
Priority to US12/030,758 priority patent/US9066962B2/en
Priority to US12/050,736 priority patent/US10066254B2/en
Priority to US14/254,483 priority patent/US9358245B2/en
Priority to US14/565,239 priority patent/US9192618B2/en
Priority to US16/053,357 priority patent/US10844417B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Definitions

  • IBS Irritable bowel syndrome
  • IBS irritable bowel syndrome
  • SIBO small intestinal bacterial overgrowth
  • IBS irritable bowel syndrome
  • IBD inflammatory bowel disease
  • LBT lactulose breath test
  • SIBO small intestinal fermentation of nutrients.
  • gas studies in IBS have been limited to the investigation of flatus. Yet, even these studies suggest the presence of excessive bacteria in IBS.
  • King, et al found the production of hydrogen by IBS subjects to be five-fold elevated implying excessive enteric bacteria (22).
  • IBS patients have excessive gas and that this gas is localized to the small intestine (11).
  • the contrasting diarrhea and constipation predominant subgroups in IBS remain unexplained.
  • the speed of transit through the small intestine is normally regulated by inhibitory mechanisms located in the proximal and distal small intestine known as the jejunal brake and the ileal brake. Inhibitory feedback is activated to slow transit when end products of digestion make contact with nutrient sensors of the small intestine.
  • inhibitory mechanisms located in the proximal and distal small intestine known as the jejunal brake and the ileal brake.
  • Inhibitory feedback is activated to slow transit when end products of digestion make contact with nutrient sensors of the small intestine.
  • Methane in the intestinal lumen has never before been reported to affect the rate of gastrointestinal transit.
  • the present invention relates to a method of manipulating the rate of gastrointestinal transit in a mammalian subject, including a human patient.
  • the method involves: (a) increasing the rate of gastrointestinal transit by causing the partial pressure of methane in the subject's intestines to be decreased; and (b) decreasing the rate of gastrointestinal transit by causing the partial pressure of methane in the subject's intestines, for example in the distal gut, to be increased.
  • constipation and disorders exhibiting constipation can be treated in subjects in whom abnormally elevated intestinal methane levels are detectable (e.g., in cases of constipation-predominant irritable bowel syndrome [IBS], pseudoobstruction, colonic inertia, postoperative ileus, encopresis, hepatic encephalopathy, or medication-induced constipation).
  • IBS constipation-predominant irritable bowel syndrome
  • the partial pressure of methane in the subject's intestines can be decreased by administering to the subject's intestinal lumen a selective inhibitor of methanogenesis, such as monensin, or a methanogen-displacing probiotic agent, or a prebiotic agent that inhibits the growth of methanogenic bacteria or promotes the growth of competing non-methanogenic intestinal flora.
  • a selective inhibitor of methanogenesis such as monensin, or a methanogen-displacing probiotic agent, or a prebiotic agent that inhibits the growth of methanogenic bacteria or promotes the growth of competing non-methanogenic intestinal flora.
  • the present invention is also directed to the use in the manufacture of a medicament for the treatment of constipation, of a selective inhibitor of methanogenesis, or of a methanogen-displacing probiotic agent, or of a prebiotic agent that inhibits the growth of methanogenic bacteria or promotes the growth of competing non-methanogenic intestinal flora.
  • the inventive method to decrease the rate of gastrointestinal transit, patients with diarrhea and disorders exhibiting diarrhea can be treated (e.g., cases of diarrhea-predominant IBS, Crohn's disease, ulcerative colitis, celiac disease, microscopic colitis, dumping syndrome, rapid transit, short bowel syndrome, post-gastrectomy syndrome, diabetic diarrhea, hyperemesis, or antibiotic-associated diarrhea).
  • the partial pressure of methane in the subject's intestines can be increased by administering methane gas to the intestinal lumen of the subject, for example into the distal segment of the intestine of the subject, or by administering to the subject a methanogenic probiotic agent or methogenesis-enhancing prebiotic agent.
  • the present invention is also directed to the use in the manufacture of a medicament for the treatment of diarrhea, of methane or a methane precursor, or of a methanogenic or other methane-enhancing probiotic agent, or of a methogenesis-enhancing prebiotic agent.
  • FIG. 1 shows a patient flow chart for a double-blind, randomized, placebo-controlled study confirming that an abnormal lactulose breath test is more prevalent in IBS than normal controls, and that antibiotic treatment in IBS leads to an improvement in symptoms and that this is based on antibiotic-induced normalization of breath test.
  • FIG. 2 shows percent improvement in composite score based on treatment and success in normalizing the LHBT.
  • Neo Neomycin.
  • FIG. 4 show the pattern of gas production with IBS symptom type, i.e., constipation-predominant IBS (unshaded bars; p ⁇ 0.00001) versus diarrhea-predominant IBS (shaded bars; p ⁇ 0.001).
  • FIG. 6 illustrates the effect on intestinal transit in dogs administered 180 ml of room air (circles) or methane gas (squares) by bolus delivery to the distal gut. Methane slowed intestinal transit.
  • C-D mean constipation minus diarrhea
  • FIG. 11 shows the percentage of subjects with IBD who produced each of the three abnormal gas patterns on LBT.
  • the partial pressure of methane in the subject's intestines can be decreased by administering to the subject's intestinal lumen a selective inhibitor of methanogenesis, such as monensim
  • a selective inhibitor of methanogenesis such as monensim
  • Useful selective inhibitors of methanogenesis include HMG-CoA reductase inhibitors known in the art (e.g., U.S. Pat. No. 5,985,907) that selectively inhibit the growth of methanogenic bacteria without significantly inhibiting the growth of non-methanogens, for example in the distal gut or colon of the subject.
  • the partial pressure of methane in the subject's intestines can be decreased by administering to the subject's intestinal lumen a methanogen-displacing probiotic agent to inhibit the growth of methanogenic bacteria therein, for example, an inoculum of a lactic acid bacterium, bifidobacterium, or probiotic Saccharomyces species, e.g., S. cerevisiae.
  • a methanogen-displacing probiotic agent to inhibit the growth of methanogenic bacteria therein
  • methanogenic bacteria for example, an inoculum of a lactic acid bacterium, bifidobacterium, or probiotic Saccharomyces species, e.g., S. cerevisiae.
  • the inoculum is typically administered in a pharmaceutically acceptable ingestible formulation, such as in a capsule, or for some subjects, consuming a food supplemented with the inoculum is effective, for example a milk, yoghurt, cheese, meat or other fermentable food preparation
  • a pharmaceutically acceptable ingestible formulation such as in a capsule
  • consuming a food supplemented with the inoculum is effective, for example a milk, yoghurt, cheese, meat or other fermentable food preparation
  • Useful probiotic agents include Bifidobacterium sp. or Lactobacillus species or strains, e.g., L. acidophilus, L. rhamnosus, L. plantarum, L. reuteri, L. paracasei subsp. paracasei, or L. casei Shirota, (P. Kontula et al., The effect of lactose derivatives on intestinal lactic acid bacteria, J. Dairy Sci.
  • the partial pressure of methane in the subject's intestines can be decreased by administering to the subject's intestinal lumen a prebiotic agent that inhibits the growth of methanogenic bacteria or promotes the growth of competing non-methanogenic intestinal flora.
  • a prebiotic agent that inhibits the growth of methanogenic bacteria or promotes the growth of competing non-methanogenic intestinal flora.
  • the partial pressure of methane in the subject's intestines can be increased by administering methane to the subject's intestinal lumen.
  • methane can be administered directly to the intestine by infusion through a tube, preferably via the rectum, but other access routes for intubation to the intestine are also useful.
  • methane can be administered to the intestinal lumen by providing a medicament comprising a catalyst and chemical substrate (i.e., a “methane precursor”) to the intestinal lumen, where they come in contact to produce methane in situ.
  • the catalyst and substrate can be administered in separate control release tablets, which release their contents in the desired location in the intestine.
  • the partial pressure of methane in the subject's intestines can be increased by administering to the subject's intestinal lumen a methane-enhancing probiotic agent.
  • a “methane-enhancing” probiotic agent is one that effectively enhances the partial pressure of methane in the subject's intestinal lumen.
  • the methane enhancing probiotic agent can be a methanogenic bacterium, such as Methanobrevibacter smithii, or certain Bacteroides spp. or Clostridium spp. (see, e.g., McKay L.
  • the partial pressure of methane in the subject's intestines can be increased by administering to the subject's intestinal lumen a prebiotic agent that enhances the growth of methanogenic bacteria.
  • proximal segment of the small bowel comprises approximately the first half of the small intestine from the pylorus to the mid-gut.
  • distal gut includes approximately the second half, from the mid-gut to the ileal-cecal valve.
  • Representative methods of administering include giving, providing, feeding or force-feeding, dispensing, inserting, injecting, infusing, perfusing, prescribing, furnishing, treating with, taking ingesting, swallowing, eating or applying.
  • Administration of inhibitors, probiotic agents, or prebiotic agents, is by well known means, including most preferably oral administration and/or enteral administration.
  • Detection of intestinal methane and other gases can be accomplished, if desired, by any suitable means or method known in the art.
  • one preferred method is breath testing.
  • breath testing E.g., P. Kerlin and L. Wong, Breath hydrogen testing in bacterial overgrowth of the small intestine, Gastroenterol. 95(4):982-88 [1988]; A Strocchi et al., Detection of malabsorption of low doses of carbohydrate: accuracy of various breath H 2 criteria, Gastroenterol. 105(5):1404-1410 [1993]; D. de Boissieu et al., [1996]; P. J.
  • Breath hydrogen or breath methane tests are based on the fact that many obligately or facultatively fermentative bacteria found in the gastrointestinal tract produce detectable quantities of hydrogen or methane gas as fermentation products from a substrate consumed by the host, under certain circumstances.
  • Substrates include sugars such as lactulose, xylose, lactose, sucrose, or glucose. The hydrogen or methane produced in the small intestine then enters the blood stream of the host and are gradually exhaled.
  • a sugar such as lactulose, xylose, lactose, or glucose
  • breath samples are taken at frequent time intervals, typically every 10 to 15 minutes for a two- to four-hour period. Samples are analyzed by gas chromatography or by other suitable techniques, singly or in combination.
  • a variable fraction of the population fails to exhale appreciable hydrogen gas during intestinal fermentation of lactulose; the intestinal microflora of these individuals instead produce more methane.
  • a non-digestible substrate other than lactulose can optionally be used.
  • Another useful method of detecting intestinal gases, such as methane, is by gas chromatography with mass spectrometry and/or radiation detection to measure breath emissions of isotope-labeled carbon dioxide, methane, or hydrogen, after administering an isotope-labeled substrate that is metabolizable by gastrointestinal bacteria but poorly digestible by the human host, such as lactulose, xylose, mannitol, or urea.
  • an isotope-labeled substrate that is metabolizable by gastrointestinal bacteria but poorly digestible by the human host, such as lactulose, xylose, mannitol, or urea.
  • a poorly digestible substrate is one for which there is a relative or absolute lack of capacity in a human for absorption thereof or for enzymatic degradation or catabolism thereof.
  • Suitable isotopic labels include 13 C or 14 C.
  • suitable isotopic labels can also include 2 H and 3 H or 17 O and 18 O, as long as the substrate is synthesized with the isotopic label placed in a metabolically suitable location in the structure of the substrate, i.e., a location where enzymatic biodegradation by intestinal microflora results in the isotopic label being sequestered in the gaseous product.
  • the isotopic label selected is a radioisotope, such as 14 C, 3 H or 15 O
  • breath samples can be analyzed by gas chromatography with suitable radiation detection means. (E.g., C. S.
  • a blinded reviewer (M.P.) interpreted the results and was asked to categorize the breath tests based on whether the test met the criteria for normal LBT.
  • a normal LBT was defined as, no rise of breath hydrogen (H 2 ) or methane (CH 4 ) concentration before 90 minutes of lactulose, with a definitive rise never more than 20 ppm during 180 minutes of measurement (18, 19, 37, 38). Studies that fell out of this range were categorized as abnormal.
  • a second set of criteria for breath test interpretation was also used whereby the traditional 2 peaks to suggest bacterial overgrowth were required. Since the two peak method was not well not as well validated a technique (37) as the parts per million (ppm), this finding was only used to compare the prevalence of this finding to healthy controls.
  • the primary outcome measure was based on a composite score (CS) calculated from the 3 main IBS symptoms (abdominal pain, diarrhea and constipation each on a scale from 0-5) to generate a score out of 15 (most severe). This was done to account for the severity of all potential IBS subgroups. Since other IBS symptoms (such as straining) would worsen or improve depending on whether patients started with diarrhea or constipation, respectively, minor criteria were not included in the CS. In addition, as reduction in colonic organisms could result in an improvement in gas and bloating, irrespective of bacterial overgrowth, gaseous symptoms too were excluded from the score. The percent improvement in the CS was then compared between placebo and neomycin In addition, the overall percent bowel normalization as determined by patient reporting was likewise compared.
  • CS composite score
  • the severity score for diarrhea and constipation were then compared between gas types.
  • a score based on the difference between constipation and diarrhea severity i.e., constipation score minus diarrhea score; “C-D” was determined.
  • the C-D was used to examine the relative weight of constipation to diarrhea in individual subjects (the more positive the score the greater the dominance the constipation was compared to diarrhea). Subjects with identical score for constipation and diarrhea severity were excluded from these analyses. This C-D score was also compared between gas types.
  • neomycin resulted in a 35.0 ⁇ 0.7% reduction in CS compared to a 11.4 ⁇ 1.3% reduction in the placebo group (p ⁇ 0.05).
  • neomycin produced a 35.4 ⁇ 0.8% reduction in CS versus a 3.7 ⁇ 1.6% reduction in the placebo group (p ⁇ 0.01). No difference was seen in subjects with a normal baseline breath test although a higher placebo rate was reported in this very small group (51%).
  • neomycin resulted in a 40.1 ⁇ 5.3% reported bowel normalization compared to 15.1 ⁇ 3.6% for placebo (p ⁇ 0.001).
  • neomycin resulted in a 44.8 ⁇ 5.6% normalization compared to 11.0 ⁇ 3.3% for placebo (p ⁇ 0.00001).
  • Neomycin was more likely to result in a true clinical response than placebo.
  • Subjects receiving placebo reported 11.0 ⁇ 3.7% normalization, subjects receiving neomycin but not successful normalization of LBT, 36.7 ⁇ 6.1% and those subjects with normal follow up LBT after neomycin reporting 75.0 ⁇ 6.4% bowel normalization (p ⁇ 0.0000001, 1-way ANOVA).
  • Neomycin although statistically more effective than placebo, was only able to normalize the breath test 20% of the time. This may be due to the large numbers and types of enteric organisms (30-33) or bacterial resistance.
  • Tc-DTPA diethylenetriaminepentaacetic acid
  • Intestinal transit was calculated by determining the area under the curve (AUC) of the cumulative percent recovery of the radioactive marker in the control (air administration) and experimental (methane administration) dogs.
  • AUC area under the curve
  • Consecutive patients referred for a lactulose breath test (LBT) to the Cedars-Sinai Medical Center, GI Motility Program from 1998-2000 completed a questionnaire designed to assess bowel symptoms as previously described (12) after approval from the institutional review board. Subjects were requested to rate the severity of nine symptoms (diarrhea, constipation, abdominal pain, bloating, sense of incomplete evacuation, straining, urgency, mucus, and gas) on a scale of 0-5, 0 signifying the absence of the symptom. The questionnaire also inquired whether subjects had Crohn's disease (CD) or ulcerative colitis (UC).
  • CD Crohn's disease
  • UC ulcerative colitis
  • IBD inflammatory bowel disease
  • Constipation-predominant IBS was identified if a subject's severity score exceeded his or her diarrhea severity score, whereas the reverse applied for diarrhea-predominant IBS.
  • Subjects who had a constipation severity score equal to the diarrhea severity score (indeterminate pattern) were excluded from the IBS subgroup analysis.
  • the percentage of IBS subjects within each abnormal gas pattern who reported constipation-predominant or diarrhea-predominant symptoms was tabulated. The prevalence of methane production between the IBS subgroups was also compared.
  • a mean C-D score was obtained by calculating the difference between the constipation and diarrhea severity scores. This was used to examine the relative weight of constipation to diarrhea in individual subjects. The C-D score was compared among the three abnormal breath gas patterns in the group as a whole and among IBS subjects.
  • a one-way ANOVA was conducted to compare symptom severity scores among the three gas patterns on LBT. Prevalance data was analyzed with a chi-square test.
  • constipation-predominant IBS was reported by 91 (37%) of the hydrogen-excreting subjects, 23 (52.3%) of the hydrogen and methane-excreting subjects and 6 (100%) of the methane-excreting subjects.
  • diarrhea-predominant IBS was observed in 105 (42.7%) of the hydrogen excretors, 6 (13.6%) of the hydrogen and methane excretors, and none of the methane excretors FIG. 10 ).
  • the predominant gas excreted by patients with IBD was hydrogen alone, detected in 47 of 49 subjects (95.9%) with Crohn's disease and 29 of 29 (100%) subjects (100%) with ulcerative colitis. ( FIG. 11 ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US10/514,188 2002-05-20 2003-05-20 Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concertration Abandoned US20060246045A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10/514,188 US20060246045A1 (en) 2002-05-20 2003-05-20 Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concertration
US12/030,758 US9066962B2 (en) 2002-05-20 2008-02-13 Method of using a probiotic microorganism for the treatment of diarrhea
US12/050,736 US10066254B2 (en) 2002-05-20 2008-03-18 Diagnosis of constipation by analysis of methane concentration
US14/254,483 US9358245B2 (en) 2002-05-20 2014-04-16 Method of treating constipation
US14/565,239 US9192618B2 (en) 2002-05-20 2014-12-09 Method of treating constipation-predominant irritable bowel syndrome
US16/053,357 US10844417B2 (en) 2002-05-20 2018-08-02 Method of distinguishing constipation predominant IBS from inflammatory bowel syndrome by analysis of methane concentration

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38217202P 2002-05-20 2002-05-20
PCT/US2003/016656 WO2003100023A2 (fr) 2002-05-20 2003-05-20 Manipulation de la vitesse du transit gastro-intestinal par modulation de la concentration de methane intestinal
US10/514,188 US20060246045A1 (en) 2002-05-20 2003-05-20 Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concertration

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/016656 A-371-Of-International WO2003100023A2 (fr) 2002-05-20 2003-05-20 Manipulation de la vitesse du transit gastro-intestinal par modulation de la concentration de methane intestinal

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/030,758 Division US9066962B2 (en) 2002-05-20 2008-02-13 Method of using a probiotic microorganism for the treatment of diarrhea
US12/050,736 Continuation-In-Part US10066254B2 (en) 2002-05-20 2008-03-18 Diagnosis of constipation by analysis of methane concentration

Publications (1)

Publication Number Publication Date
US20060246045A1 true US20060246045A1 (en) 2006-11-02

Family

ID=29584369

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/514,188 Abandoned US20060246045A1 (en) 2002-05-20 2003-05-20 Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concertration
US12/030,758 Active 2024-08-21 US9066962B2 (en) 2002-05-20 2008-02-13 Method of using a probiotic microorganism for the treatment of diarrhea
US14/254,483 Expired - Lifetime US9358245B2 (en) 2002-05-20 2014-04-16 Method of treating constipation
US14/565,239 Expired - Fee Related US9192618B2 (en) 2002-05-20 2014-12-09 Method of treating constipation-predominant irritable bowel syndrome

Family Applications After (3)

Application Number Title Priority Date Filing Date
US12/030,758 Active 2024-08-21 US9066962B2 (en) 2002-05-20 2008-02-13 Method of using a probiotic microorganism for the treatment of diarrhea
US14/254,483 Expired - Lifetime US9358245B2 (en) 2002-05-20 2014-04-16 Method of treating constipation
US14/565,239 Expired - Fee Related US9192618B2 (en) 2002-05-20 2014-12-09 Method of treating constipation-predominant irritable bowel syndrome

Country Status (10)

Country Link
US (4) US20060246045A1 (fr)
EP (2) EP1505989B1 (fr)
JP (1) JP2005526861A (fr)
AT (1) ATE499107T1 (fr)
AU (1) AU2003273141B2 (fr)
CA (2) CA2771788C (fr)
DE (1) DE60336128D1 (fr)
ES (3) ES2361007T3 (fr)
PT (1) PT1505989E (fr)
WO (1) WO2003100023A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080182291A1 (en) * 2002-05-20 2008-07-31 Cedars-Sinai Medical Center Diagnosis of constipation by analysis of methane concentration
US20130011384A1 (en) * 2010-03-26 2013-01-10 Morgavi Diego P Use of a Material, Produced from Fungal Fermentation, as a Food Supplement
WO2014152754A2 (fr) * 2013-03-15 2014-09-25 Cedars-Sinai Medical Center Méthodes de diagnostic, de sélection et de traitement de maladies et d'états causés par ou associés à des bactéries méthanogènes
US9066962B2 (en) 2002-05-20 2015-06-30 Cedars-Sinai Medical Center Method of using a probiotic microorganism for the treatment of diarrhea
US9289418B2 (en) 2013-03-15 2016-03-22 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US9956292B2 (en) 2014-08-13 2018-05-01 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
US11103157B2 (en) * 2015-09-02 2021-08-31 Cedars-Sinai Medical Center Breath gas analysis

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2971123B1 (fr) * 2011-02-08 2013-11-22 Solvay Galactofructose pour son effet regulateur du transit intestinal
KR101611212B1 (ko) 2014-11-19 2016-04-12 한국생명공학연구원 메탄균 생육저해 미생물 및 그 용도
KR20170122835A (ko) * 2015-03-16 2017-11-06 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) 생체활성 동물 사료 중의 고세균, 조성물을 제조하는 방법 및 조성물을 사용하는 방법
WO2020002543A1 (fr) 2018-06-27 2020-01-02 Sutherland Duncan Bruce Procédé de préparation d'une composition comprenant des cellules d'archéobactéries méthanobrevibacter tuées ou inactivées et composition ainsi obtenue
CN111671791A (zh) * 2020-05-25 2020-09-18 中山大学 一种靶向肠道菌群改善便秘的微生态组合物及其制剂
AU2021396978A1 (en) 2020-12-08 2023-02-23 Ruminant Biotech Corp Limited Improvements to devices and methods for delivery of substances to animals

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447850A (en) * 1994-01-31 1995-09-05 Mccann; James L. Method of producing methane from organic waste
US5889038A (en) * 1996-03-20 1999-03-30 Children's Hospital Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
US6299774B1 (en) * 2000-06-26 2001-10-09 Jack L. Ainsworth Anaerobic digester system
US6328959B1 (en) * 1998-09-18 2001-12-11 The United States Of America As Represented By The Secretary Of The Navy Intestinal hydrogen removal using hydrogen-metabolizing microbes
US6368591B2 (en) * 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
US6558708B1 (en) * 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6805852B2 (en) * 1999-08-11 2004-10-19 Cedars-Sinai Medical Center Methods of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB423083A (en) * 1934-05-22 1935-01-24 Hugh Edwin Johnstone Peake Improvements in and relating to the manufacture of fermented beverages and medicinalpreparations
JPS60133852A (ja) * 1983-12-23 1985-07-17 Zenkoku Shokubutsu Tanpaku Shokuhin Kyodo Kumiai 新規な納豆製品
DE3718638A1 (de) * 1987-06-04 1988-12-22 Thomae Gmbh Dr K Neue phenylethanolamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH03275630A (ja) * 1990-03-23 1991-12-06 Hayashikane Sangyo Kk 肝機能改善剤及び肝機能改善食品又は飲料
ATE262349T1 (de) * 1993-10-19 2004-04-15 Commw Scient Ind Res Org Methode zur verbesserung der nahrungsverwertung von wiederkäuern oder wiederkäuer-ähnlichen tieren
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
JP3010007B2 (ja) * 1995-05-22 2000-02-14 ビオフェルミン製薬株式会社 配合下剤
CN1119154C (zh) * 1998-01-20 2003-08-27 上海信谊药业有限公司 双歧三联活菌制剂及制备方法
US5985907A (en) 1998-08-12 1999-11-16 Health Research, Inc. Method for inhibiting growth of methanogens
DE60122881T2 (de) * 2000-06-13 2007-01-11 Unilever N.V. Nicht-lebensfähigen lactobacillus enthaltendes lebensmittelprodukt
US10066254B2 (en) 2002-05-20 2018-09-04 Cedars-Sinai Medical Center Diagnosis of constipation by analysis of methane concentration
EP1505989B1 (fr) 2002-05-20 2011-02-23 Cedars-Sinai Medical Center Manipulation de la vitesse du transit gastro-intestinal par modulation de la concentration de methane intestinal
ITBO20020564A1 (it) * 2002-09-06 2004-03-07 Alfa Wassermann Spa Bifidobatteri e preparazioni che li contengono.

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447850A (en) * 1994-01-31 1995-09-05 Mccann; James L. Method of producing methane from organic waste
US6558708B1 (en) * 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US5889038A (en) * 1996-03-20 1999-03-30 Children's Hospital Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
US6495567B1 (en) * 1996-03-20 2002-12-17 Beth Israel Deaconess Medical Center Triaryl methane compounds and their use in the treatment of diarrhea and scours
US6368591B2 (en) * 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
US6328959B1 (en) * 1998-09-18 2001-12-11 The United States Of America As Represented By The Secretary Of The Navy Intestinal hydrogen removal using hydrogen-metabolizing microbes
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6805852B2 (en) * 1999-08-11 2004-10-19 Cedars-Sinai Medical Center Methods of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6299774B1 (en) * 2000-06-26 2001-10-09 Jack L. Ainsworth Anaerobic digester system

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080182291A1 (en) * 2002-05-20 2008-07-31 Cedars-Sinai Medical Center Diagnosis of constipation by analysis of methane concentration
US10066254B2 (en) 2002-05-20 2018-09-04 Cedars-Sinai Medical Center Diagnosis of constipation by analysis of methane concentration
US9358245B2 (en) 2002-05-20 2016-06-07 Cedars-Sinai Medical Center Method of treating constipation
US10844417B2 (en) 2002-05-20 2020-11-24 Cedars-Sinai Medical Center Method of distinguishing constipation predominant IBS from inflammatory bowel syndrome by analysis of methane concentration
US9066962B2 (en) 2002-05-20 2015-06-30 Cedars-Sinai Medical Center Method of using a probiotic microorganism for the treatment of diarrhea
US9192618B2 (en) 2002-05-20 2015-11-24 Cedars-Sinai Medical Center Method of treating constipation-predominant irritable bowel syndrome
US20130011384A1 (en) * 2010-03-26 2013-01-10 Morgavi Diego P Use of a Material, Produced from Fungal Fermentation, as a Food Supplement
CN111494375A (zh) * 2013-03-15 2020-08-07 雪松-西奈医学中心 由产甲烷菌引起或与之相关的疾病和病状的诊断、选择和治疗方法
WO2014152754A2 (fr) * 2013-03-15 2014-09-25 Cedars-Sinai Medical Center Méthodes de diagnostic, de sélection et de traitement de maladies et d'états causés par ou associés à des bactéries méthanogènes
US10688149B2 (en) 2013-03-15 2020-06-23 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US9845511B2 (en) 2013-03-15 2017-12-19 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
CN105208861A (zh) * 2013-03-15 2015-12-30 雪松-西奈医学中心 由产甲烷菌引起或与之相关的疾病和病状的诊断、选择和治疗方法
US9744208B2 (en) * 2013-03-15 2017-08-29 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US10226505B2 (en) 2013-03-15 2019-03-12 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
AU2014239164B2 (en) * 2013-03-15 2018-12-06 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US20160038562A1 (en) * 2013-03-15 2016-02-11 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
WO2014152754A3 (fr) * 2013-03-15 2014-12-04 Cedars-Sinai Medical Center Méthodes de diagnostic, de sélection et de traitement de maladies et d'états causés par ou associés à des bactéries méthanogènes
US10519515B2 (en) 2013-03-15 2019-12-31 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US9289418B2 (en) 2013-03-15 2016-03-22 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US9956292B2 (en) 2014-08-13 2018-05-01 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
US10668159B2 (en) 2014-08-13 2020-06-02 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
US10328151B2 (en) 2014-08-13 2019-06-25 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
US11344501B2 (en) 2014-08-13 2022-05-31 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
US11590102B2 (en) 2015-04-01 2023-02-28 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
US11103157B2 (en) * 2015-09-02 2021-08-31 Cedars-Sinai Medical Center Breath gas analysis

Also Published As

Publication number Publication date
WO2003100023A2 (fr) 2003-12-04
JP2005526861A (ja) 2005-09-08
EP1505989B1 (fr) 2011-02-23
WO2003100023A3 (fr) 2004-04-08
ES2361008T3 (es) 2011-06-13
CA2486585C (fr) 2012-07-10
US20150099713A1 (en) 2015-04-09
EP2251017B1 (fr) 2015-03-25
US9192618B2 (en) 2015-11-24
US9358245B2 (en) 2016-06-07
ATE499107T1 (de) 2011-03-15
CA2771788C (fr) 2022-03-22
EP1505989A2 (fr) 2005-02-16
PT1505989E (pt) 2011-03-29
EP1505989A4 (fr) 2007-05-09
US9066962B2 (en) 2015-06-30
EP2251017A1 (fr) 2010-11-17
AU2003273141A1 (en) 2003-12-12
CA2771788A1 (fr) 2003-12-04
AU2003273141B2 (en) 2009-05-07
ES2361007T3 (es) 2011-06-13
CA2486585A1 (fr) 2003-12-04
US20140228431A1 (en) 2014-08-14
US20080138320A1 (en) 2008-06-12
ES2535489T3 (es) 2015-05-12
DE60336128D1 (de) 2011-04-07

Similar Documents

Publication Publication Date Title
US9192618B2 (en) Method of treating constipation-predominant irritable bowel syndrome
US10844417B2 (en) Method of distinguishing constipation predominant IBS from inflammatory bowel syndrome by analysis of methane concentration
Pimentel et al. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study
Singh et al. Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis
Madden et al. A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics
Moré et al. Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis–a review
Masiero et al. Pneumonia in stroke patients with oropharyngeal dysphagia: a six-month follow-up study
Fiorini et al. Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection
Cremonini et al. Effect of Different Probiotic Preparations on Anti-Helicobacter PyloriTherapy-Related Side Effects: A Parallel Group, Triple Blind, Placebo-Controlled Study
Federico et al. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection
Lacy et al. Pathophysiology, evaluation, and treatment of bloating: hope, hype, or hot air?
Dukowicz et al. Small intestinal bacterial overgrowth: a comprehensive review
García-Collinot et al. Effectiveness of Saccharomyces boulardii and metronidazole for small intestinal bacterial overgrowth in systemic sclerosis
Klaus et al. Small intestinal bacterial overgrowth mimicking acute flare as a pitfall in patients with Crohn's Disease
Airaksinen et al. The effect of a probiotic blend on gastrointestinal symptoms in constipated patients: a double blind, randomised, placebo controlled 2-week trial
Burta et al. Efficacy and safety of APT036 versus simethicone in the treatment of functional bloating: a multicentre, randomised, double-blind, parallel group, clinical study
Gerson et al. A prospective study of oesophageal 24-h ambulatory pH monitoring in patients with functional dyspepsia
Imhoff et al. Is There a Future for Probiotics in Preventing Clostridium difficile–Associated Disease and Treatment of Recurrent Episodes?
TWI384990B (zh) 用於治療胃潰瘍之乳酸菌菌株之食品組成物以及醫藥組成物
Sun et al. Effect of probiotics and dietary fiber combined with pinaverium bromide on intestinal flora in patients with irritable bowel syndrome
Szymański et al. Efficacy of Lactobacillus Reuteri DSM 17938 for the treatment of acute gastroenteritis in children: protocol of a randomized controlled trial
Porru et al. Oral D mannose in the prevention and treatment of recurrent urinary tract infections: A review
Saboowala Small Intestinal Bacterial Overgrowth (SIBO): Pathogenesis, Manifestations, Diagnosis, Diet, Treatment & More. A Concise Review.
Hasler Gas/Bloat Syndromes
Young et al. Bacterial Overgrowth

Legal Events

Date Code Title Description
AS Assignment

Owner name: CEDARS-SINAI MEDICAL CENTER, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIN, HENRY C.;PIMENTEL, MARK;REEL/FRAME:016114/0464;SIGNING DATES FROM 20050307 TO 20050607

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION